DOI QR코드

DOI QR Code

The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study

  • Han, Seunghee (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Joon-Il (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Park, Michael Yong (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Moon Hyung (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Rha, Sung Eun (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Young Joon (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 투고 : 2017.05.13
  • 심사 : 2018.01.02
  • 발행 : 2018.08.01

초록

Objective: To preliminarily evaluate the diagnostic performance of an unenhanced MRI for detecting hepatocellular carcinoma (HCC) with a case-control study design. Materials and Methods: The case group consisted of 175 patients with initially-diagnosed HCC, who underwent a 3T liver MRI. A total of 237 HCCs were identified. The number of HCCs that were smaller than 1 cm, 1 cm ${\leq}$ and < 2 cm, and ${\geq}2cm$ were 19, 105, and 113, respectively. For the control group, 72 patients with chronic liver disease, who did not have HCC, were enrolled. Two radiologists independently reviewed the T2 half-Fourier acquisition single-shot turbo spin echo, T2 fast spin echos with fat saturation, T1 gradient in- and out-of-phase images, and diffusion-weighted images/apparent diffusion coefficient maps to detect HCC. Per-patient analyses were performed to evaluate the sensitivity and specificity of the non-contrast MRI for diagnosing HCC. Furthermore, the per-lesion sensitivity was also calculated according to tumor size. Results: In the per-patient analyses, the sensitivity and specificity of reader 1 were 86.3% (151/175) and 87.5% (63/72), respectively; while those of reader 2 were 82.9% (145/175) and 76.4% (55/72), respectively. When excluding HCCs smaller than 1 cm, the sensitivity of reader 1 and 2 were 88.0% (147/167) and 86.2% (144/167), respectively. In the per-lesion analyses, the sensitivities of reader 1 and reader 2 were 75.9% (180/237) and 70.5% (167/237), respectively. Conclusion: The per-patient sensitivity and specificity of non-contrast MRIs were within a reasonable range for the initial diagnosis of HCC. Non-contrast MRIs may have a potential for surveillance of HCC. Further confirmatory diagnostic test accuracy studies are needed.

키워드

과제정보

연구 과제 주관 기관 : Ministry of Health & Welfare

참고문헌

  1. Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006;12:7239-7249 https://doi.org/10.3748/wjg.v12.i45.7239
  2. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011;21:401-416 https://doi.org/10.2188/jea.JE20100190
  3. Meissner HI, Smith RA, Rimer BK, Wilson KM, Rakowski W, Vernon SW, et al. Promoting cancer screening: learning from experience. Cancer 2004;101(5 Suppl):1107-1117 https://doi.org/10.1002/cncr.20507
  4. Tan CH, Low SC, Thng CH. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol 2011;2011:519783
  5. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422
  6. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
  7. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474 https://doi.org/10.1007/s12072-010-9165-7
  8. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943 https://doi.org/10.1016/j.jhep.2011.12.001
  9. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for earlystage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47 https://doi.org/10.1111/j.1365-2036.2009.04014.x
  10. Kim YK, Kim YK, Park HJ, Park MJ, Lee WJ, Choi D. Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for detecting liver malignancy in patients with high risk for hepatocellular carcinoma. Magn Reson Imaging 2014;32:610-618 https://doi.org/10.1016/j.mri.2013.12.021
  11. Yoon JH, Park JW, Lee JM. Noninvasive diagnosis of hepatocellular carcinoma: elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea practice guidelines compared with other guidelines and remaining issues. Korean J Radiol 2016;17:7-24 https://doi.org/10.3348/kjr.2016.17.1.7
  12. Korean Society of Abdominal Radiology. Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-443 https://doi.org/10.3348/kjr.2017.18.3.427
  13. Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acidenhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 2015;25:2859-2868 https://doi.org/10.1007/s00330-015-3686-3
  14. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-523 https://doi.org/10.1111/j.1572-0241.2006.00467.x
  15. Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, et al. Small ($\leq$1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 2014;271:748-760 https://doi.org/10.1148/radiol.14131996
  16. Davarpanah AH, Weinreb JC. The role of imaging in hepatocellular carcinoma: the present and future. J Clin Gastroenterol 2013;47 Suppl:S7-S10 https://doi.org/10.1097/MCG.0b013e31827f0d3d
  17. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-468 https://doi.org/10.1159/000343875
  18. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157 https://doi.org/10.1148/radiol.2431062144
  19. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther 2013;38:303-312 https://doi.org/10.1111/apt.12370
  20. Lim KS. Diffusion-weighted MRI of hepatocellular carcinoma in cirrhosis. Clin Radiol 2014;69:1-10 https://doi.org/10.1016/j.crad.2013.07.022
  21. Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, et al. Hepatic metastases: diffusion-weighted sensitivityencoding versus SPIO-enhanced MR imaging. Radiology 2006;239:122-130 https://doi.org/10.1148/radiol.2383041384
  22. Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012;264:761-770 https://doi.org/10.1148/radiol.12112517
  23. Yoo H, Lee JM, Yoon JH, Kang HJ, Lee SM, Yang HK, et al. T2* mapping from multi-echo dixon sequence on gadoxetic acid-enhanced magnetic resonance imaging for the hepatic fat quantification: can it be used for hepatic function assessment? Korean J Radiol 2017;18:682-690 https://doi.org/10.3348/kjr.2017.18.4.682
  24. Xie S, Li Q, Cheng Y, Zhang Y, Zhuo Z, Zhao G, et al. Impact of liver fibrosis and fatty liver on T1rho measurements: a prospective study. Korean J Radiol 2017;18:898-905 https://doi.org/10.3348/kjr.2017.18.6.898
  25. Ahn JH, Yu JS, Cho ES, Chung JJ, Kim JH, Kim KW. Diffusionweighted MRI of malignant versus benign portal vein thrombosis. Korean J Radiol 2016;17:533-540 https://doi.org/10.3348/kjr.2016.17.4.533
  26. Lee GM, Kim YR, Ryu JH, Kim TH, Cho EY, Lee YH, et al. Quantitative measurement of hepatic fibrosis with gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic hepatitis B infection: a comparative study on aspartate aminotransferase to platelet ratio index and fibrosis-4 index. Korean J Radiol 2017;18:444-451 https://doi.org/10.3348/kjr.2017.18.3.444
  27. Yoon JH, Lee JM, Yu MH, Kim EJ, Han JK. Triple arterial phase MR imaging with gadoxetic acid using a combination of contrast enhanced time robust angiography, keyhole, and viewsharing techniques and two-dimensional parallel imaging in comparison with conventional single arterial phase. Korean J Radiol 2016;17:522-532 https://doi.org/10.3348/kjr.2016.17.4.522
  28. Hardie AD, Kizziah MK, Rissing MS. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadoliniumenhanced MRI using liver explantation standard. J Comput Assist Tomogr 2011;35:711-715 https://doi.org/10.1097/RCT.0b013e31823421ac
  29. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004;19:1159-1172 https://doi.org/10.1111/j.1365-2036.2004.01963.x
  30. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679-690 https://doi.org/10.1111/j.1572-0241.2003.07327.x
  31. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418-1424 https://doi.org/10.1016/j.cgh.2008.08.005
  32. Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, et al.; Italian Liver Cancer (ITA.LI.CA) Group. Costeffectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. J Hepatol 2012;56:1089-1096 https://doi.org/10.1016/j.jhep.2011.11.022
  33. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422-434 https://doi.org/10.1016/S0002-9343(96)00197-0
  34. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-259 https://doi.org/10.1136/gut.48.2.251

피인용 문헌

  1. Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study vol.20, pp.12, 2018, https://doi.org/10.3348/kjr.2019.0363
  2. Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency vol.21, pp.12, 2020, https://doi.org/10.3348/kjr.2020.1322
  3. Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance vol.20, pp.1, 2020, https://doi.org/10.17998/jlc.20.1.25
  4. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort vol.30, pp.4, 2018, https://doi.org/10.1007/s00330-019-06546-5
  5. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepat vol.30, pp.8, 2018, https://doi.org/10.1007/s00330-020-06754-4
  6. Imaging Modalities for Hepatocellular Carcinoma Surveillance: Expanding Horizons beyond Ultrasound vol.20, pp.2, 2020, https://doi.org/10.17998/jlc.20.2.99
  7. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance vol.40, pp.7, 2018, https://doi.org/10.1148/rg.2020200104
  8. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI vol.6, pp.None, 2020, https://doi.org/10.20517/2394-5079.2020.50
  9. Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients vol.18, pp.7, 2021, https://doi.org/10.3390/ijerph18073598
  10. Meta-Analysis of the Accuracy of Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: Non-Contrast versus Hepatobiliary Phase-Abbreviated Magnetic Resonance Imaging vol.13, pp.12, 2018, https://doi.org/10.3390/cancers13122975
  11. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis vol.75, pp.1, 2018, https://doi.org/10.1016/j.jhep.2021.01.041
  12. United adversarial learning for liver tumor segmentation and detection of multi-modality non-contrast MRI vol.73, pp.None, 2018, https://doi.org/10.1016/j.media.2021.102154
  13. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? vol.20, pp.1, 2022, https://doi.org/10.1016/j.cgh.2021.02.036